EN

Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute ...

DOUBEK, Michael, Jan MUŽÍK, Tomáš SZOTKOWSKI, Vladimír KOZA, Petr CETKOVSKÝ, Tomáš KOZÁK, Pavel ŽÁK, Jaroslava VOGLOVÁ, Soňa ŠTRUNCOVÁ, Ladislav DUŠEK a Karel INDRÁK. Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT). Neoplasma, Bratislava, 2007, roč. 54, č. 1, s. 89-94. ISSN 0028-2685.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)
Název česky Je FLT3 tandemová duplikace významným indikátorem pro alogenní transplantaci u akutní myeloidní leukémie? Analýza pacientů registru akutních leukémií (ALERT)
Název anglicky Is FLT3 internal tandem duplication significant indicator for allogeneic transplantation in acute myeloid leukemia? An analysis of patients from the Czech Acute Leukemia Clinical Register (ALERT)
Autoři DOUBEK, Michael (203 Česká republika, garant), Jan MUŽÍK (203 Česká republika), Tomáš SZOTKOWSKI (203 Česká republika), Vladimír KOZA (203 Česká republika), Petr CETKOVSKÝ (203 Česká republika), Tomáš KOZÁK (203 Česká republika), Pavel ŽÁK (203 Česká republika), Jaroslava VOGLOVÁ (203 Česká republika), Soňa ŠTRUNCOVÁ (203 Česká republika), Ladislav DUŠEK (203 Česká republika) a Karel INDRÁK (203 Česká republika).
Vydání Neoplasma, Bratislava, 2007, 0028-2685.
Další údaje
Originální jazyk čeština
Typ výsledku Článek v odborném periodiku
Obor 3.2 Clinical medicine
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 1.208
Kód RIV RIV/00216224:14110/07:00032737
Organizační jednotka Lékařská fakulta
UT WoS 000246073100014
Klíčová slova anglicky HUMAN HEMATOLOGIC MALIGNANCIES; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FLT3-ACTIVATING MUTATIONS; PROGNOSTIC-SIGNIFICANCE; RISK GROUP; 12 TRIALS; AML 10; CYTOGENETICS; EXPRESSION
Štítky 12 TRIALS, ACUTE MYELOGENOUS LEUKEMIA, ACUTE PROMYELOCYTIC LEUKEMIA, AML 10, cytogenetics, Expression, FLT3-ACTIVATING MUTATIONS, HUMAN HEMATOLOGIC MALIGNANCIES, PROGNOSTIC-SIGNIFICANCE, RISK GROUP
Změnil Změnil: prof. RNDr. Ladislav Dušek, Ph.D., učo 670. Změněno: 1. 4. 2010 09:37.
Anotace
AML patients, we performed an analysis of all patients with FLT3 mutations registered in the Czech Acute Leukemia Clinical Register (ALERT) from 2003 till the end of 2005. Within the mentioned period 170 patients with AML of median age 56 years (23-77) were investigated for FLT3 mutation, within them 36 cases (21 %) with FLT3 mutations (32 FLT3 ITD and 4 FLT3 D835) were found.Out of FLT3 ITD positive patients 13 had allogeneic transplantation, 20 patients with mutations of FLT3 were treated with chemotherapy without transplantation. Results of the treatment of these patients were compared with the results of the group of patients without FLT3 mutation, which was according to other characteristics identical with the group of patients with FLT3 mutations (n=134). Median overall survival (OS) was significantly shorter for patients with FLT3 ITD (34.8 weeks) than for those without FLT3 mutations (67.7 weeks; P=0.028). Median OS of patients with FLT3 ITD who had allogeneic transplantation was 42.5 weeks; median OS of patients with FLT3 ITD treated only with chemotherapy was 29.6 weeks (P=0.362). After allogeneic transplantation, median OS of FLT3 mutations negative patients was similar to FLT3 ITD positive patients (46.7 versus 42.5 weeks; P=0.443). Our results suggest that at present there is no strong evidence that FLT3 status alone should influence the decision to proceed to allogeneic transplantation in AML patients.
Anotace anglicky
AML patients, we performed an analysis of all patients with FLT3 mutations registered in the Czech Acute Leukemia Clinical Register (ALERT) from 2003 till the end of 2005. Within the mentioned period 170 patients with AML of median age 56 years (23-77) were investigated for FLT3 mutation, within them 36 cases (21 %) with FLT3 mutations (32 FLT3 ITD and 4 FLT3 D835) were found.Out of FLT3 ITD positive patients 13 had allogeneic transplantation, 20 patients with mutations of FLT3 were treated with chemotherapy without transplantation. Results of the treatment of these patients were compared with the results of the group of patients without FLT3 mutation, which was according to other characteristics identical with the group of patients with FLT3 mutations (n=134). Median overall survival (OS) was significantly shorter for patients with FLT3 ITD (34.8 weeks) than for those without FLT3 mutations (67.7 weeks; P=0.028). Median OS of patients with FLT3 ITD who had allogeneic transplantation was 42.5 weeks; median OS of patients with FLT3 ITD treated only with chemotherapy was 29.6 weeks (P=0.362). After allogeneic transplantation, median OS of FLT3 mutations negative patients was similar to FLT3 ITD positive patients (46.7 versus 42.5 weeks; P=0.443). Our results suggest that at present there is no strong evidence that FLT3 status alone should influence the decision to proceed to allogeneic transplantation in AML patients.
Návaznosti
MSM0021622412, záměrNázev: Interakce mezi chemickými látkami, prostředím a biologickými systémy a jejich důsledky na globální, regionální a lokální úrovni (INCHEMBIOL) (Akronym: INCHEMBIOL)
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Výzkumné záměry
VytisknoutZobrazeno: 22. 4. 2019 00:22

Další aplikace